Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay. by 배숭준 et al.
RESEARCH ARTICLE
Chemosensitivity to doxorubicin of ER-
positive/HER2-negative breast cancers with
high 21-gene recurrence score: A study based
on in vitro chemoresponse assay
Sung Gwe Ahn1, Soong June Bae1, Changik Yoon1, Yoon Jin Cha2, Hak Woo Lee1, Seung
Ah Lee3, Joon Jeong1*
1 Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul,
Korea, 2 Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine,




The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individu-
als with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay,
we compared the chemosensitivity according to RS in these patients.
Method
Among the patients with Oncotype Dx assay, we identified 63 patients who had chemother-
apy response assays to doxorubicin based on adenosine triphosphate. The degree of che-
mosensitivity to doxorubicin was translated into the cell death rate (CDR). The RS was also
dichotomized with a cutoff of 26.
Results
Of 63 patients, 34 (54%), 17 (27%), and 12 patients (19%) had a low, intermediate, and high
RS, respectively. The mean CDR differed significantly according to categorized RS, with
17.3±10.8 in the low RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in
the high RS group (P = 0.024, One-way ANOVA test). The mean CDR was significantly
higher in the higher RS (26) group compared with the lower RS (<26) group (P = 0.025,
the Student’s t-test), as well as in the high RS (>30) group compared with the low RS (<18)
group (P = 0.012, the Student’s t-test). Also, continuous RS and CDR correlated positively
(Pearson’s R = 0.337; P = 0.007). High RS demonstrated the odds ratio (OR = 26.33; 95%
CI = 1.69–410.0) for predicting tumors with chemosensitivity on the multivariate analysis.
Conclusions
The chemosensitivity measured by in vitro chemoresponse assay was different according to
the RS. Our findings support that tumors with high RS has the chemosensitivity even though
they are luminal/HER2-negative tumors.
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Background
It has been widely recognized that a substantial number of patients with estrogen receptor
(ER)-positive breast cancer would have been adequately treated with endocrine therapy alone
[1, 2]. The Early Breast Cancer Trialists meta-analysis have shown that the addition of chemo-
therapy does not offer significant benefit but exposes toxicity from cytotoxic chemotherapy in
a majority of patients with ER-positive/human epidermal growth factor receptor2 (HER2)-
negative tumors [3, 4]. To select patients who could be spared adjuvant chemotherapy, the use
of molecular signatures and their validations are regarded as a high priority [5].
Currently, several multigene assays are available for clinicians to identify the appropriate
patients who might derive a clinical benefit from chemotherapy [6]. Among several multigene
assays which help to determine chemotherapy or not in ER-positive tumors, the 21-gene recur-
rence score (RS) became the first clinically validated multi-gene assay with the use of archival
tumor specimens from completed studies that used a prospective–retrospective design [7, 8].
Also, it has been incorporated into clinical guidelines concerning treatment decisions with a
high level of recommendation6 and has become widespread in actual practice [9].
It is easily elicited that survival benefit by the addition of adjuvant chemotherapy is associ-
ated with responsiveness to chemotherapy. Thus, it might be assumed that tumors with high
RS would have a relatively higher response to neoadjuvant chemotherapy (NAC) compared
with tumors with low or intermediate RS. Indeed, previous studies have shown that tumors
with high RS have a higher rate of pathologic complete response (pCR) in neoadjuvat setting
[10, 11].
To predict responsiveness to chemotherapy in individual tumors using in vitro assays, sev-
eral methods are developed and tested. Among these assays, in vitro CRAs using adenosine tri-
phosphate (ATP-CRAs) can be performed relatively quickly and have overcome the technical
problems caused by fibroblast contamination [12, 13]. Previously we provided evidence that
ATP-CRAs for breast tumors could effectively reflect the tumor response to chemotherapy
observed in neoadjuvant setting [12].
In this study, we wondered whether tumors with high RS might have a higher chemosensi-
tivity to doxorubicin superior to tumors with low RS based on ATP-CRAs. Using in vitro
assay, we aim to know biological difference among ER-positive/HER2-negative tumors
according to RS in context of chemotherapy-responsiveness.
Methods
Patients
The institutional review board of Gangnam Severance Hospital, Yonsei University, Seoul,
Korea, approved the study to be in accordance with good clinical practice guidelines and the
Declaration of Helsinki. The need for informed consent was waived due to the retrospective
design under the approval of the institutional review board. Between August 2011 and June
2016, 244 patients underwent Oncotype DX testing at Gangnam Severance Hospital and Sev-
erance Hospital, Yonsei University College of Medicine. All patients had ER-positive, HER2-
negative breast cancer. Of these patients, we identified 63 patients who donated their tumor
samples for ATP-CRAs with doxorubicin. The degree of chemosensitivity to doxorubicin
was translated into the cell death rate (CDR). Raw data of these patients is provided online
(S1 Data).
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Immunohistochemical method
For our IHC study of four markers, formalin-fixed, paraffin-embedded tissue sections
obtained from surgical specimens were stained with appropriate antibodies specific for the ER
(1:100 clone 6F11; Novocastra, Newcastle upon Tyne, UK), progesterone receptor (PR; clone
16; Novocastra), and Ki-67 (MIB-1; Dako, Glostrup, Denmark). ER and PR IHC test results
were stratified into four groups using the modified Allred system: strong, Allred score 7–8;
moderate, Allred score 5–6; weak, Allred score 2–4; and negative, Allred score 0–1 [14]. Ki67
expression was measured by an experienced pathologist and presented as a percentage score
(range 0–100%) of positive tumor cells.
Oncotype Dx assays
RS is calculated by the Oncotype Dx assay. It is a continuous score that is classified into the fol-
lowing categories: low risk (RS< 18), intermediate risk (RS 18–30), and high risk (RS31).
The Oncotype DX assay was performed using RNA extracted from formalin-fixed paraffin-
embedded tissue and supplied by Genomic Health (Redwood City, CA, USA). After a review
of hematoxylin and eosin-stained slides to determine whether sufficient invasive breast cancer
was present and whether manual microdissection was indicated, RNA was extracted from the
unstained sections. Cases with no cancer (depleted by prior tissue studies) or with cancer cells
occupying <5% of the section area were excluded from the assay. The RS was also dichoto-
mized with a cutoff of 26 following an ongoing clinical trial as TAILORX.2,14
In vitro chemoresponse assays using adenosine triphosphate
(ATP-CRAs)
Tumor tissues were stored in Hank’s balanced salt solution (Gibco BRL, Rockville, MD, USA)
containing100 IU/ml penicillin (Sigma, St. Louis, MO, USA), 100 mg/ml streptomycin
(Sigma), 100 mg/ml gentamicin (Gibco BRL), 2.5 mg/ml amphotericin B (Gibco BRL) and 5%
fetal bovine serum (Gibco BRL) on operation day. After histological evaluation, within 24 h
after operation, the tumor tissues were incubated in a mixture of dispase (Sigma), pronase
(Sigma) and DNase (Sigma) for 12–16 hours at 37˚C. Isolated cells were separated from tissue
fragments by passing through a cell strainer (BD Falcon, Bedford, MA, USA). Tumor cells
were separated from dead cells and red blood cells using Ficoll gradient (1.077 g/ml) centrifu-
gation at 400g for 15 min. When a sufficient amount of cells were isolated, blood-derived nor-
mal cells were removed using CD45 antibody-conjugated magnetic beads (Miltenyi Biotech,
Auburn, CA, USA). The separated tumor cell preparation was suspended in IMDM (Gibco
BRL) including 10% FBS and antibiotics, as mentioned above. Cells were diluted to concentra-
tions between 5000 and 20,000 viable cells/100 ml for plating into a 96-well ultralow attach-
ment microplate (Costar, Cambridge, MA, USA), with or without anti-cancer drugs, and
cultured for 48 h in a CO2 incubator.
Treated drug concentrations (TDC) were determined by preliminary experiments that
showed the scattered distribution of cell death from each specimen The TDC for doxorubicin
was 1.5 mg/ml; To measure ATP levels, ATP in the cell lysate was reacted with luciferin
(Roche, Mannheim, Germany) and excessive luciferase was measured using a Victor 3 multi-
label counter (PerkinElmer, Boston, MA, USA). Excel-based raw data were analyzed using
Report Maker version 1.1 (ISU ABXIS, Seoul, Korea). Briefly, the cell death rate for each drug
was calculated as follows: Cell death rate (CDR) (%) = (1 - [mean luminescence in treated
group/mean luminescence in untreated controls group])X100. To calculate the intra-assay
mean coefficient of variation (CV), luminescence values of each specimen were measured 3–6
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times in negative and positive control groups. We next determined whether the measured val-
ues at 280 pg ATP were higher than at 105 pg ATP. The test was considered a failure if micro-
organism contamination was present, there was an inadequate number of cells, or if the intra-
assay mean CV exceeded 30. In addition, if the measured values in the untreated control group
were lower than that in the positive group (105 pg ATP), the specimen was considered to have
unacceptable viability.
Statistical analysis
Discrete variables were compared using the χ2 test or Fisher’s exact test. Student’s t-test or a
one-way analysis of variation (ANOVA) test was used to compare means. Pearson’s R was cal-
culated to measure the correlative value between the RS and CDR. The binary logistic regres-
sion models were employed to predict tumors with chemosensitivity. SPSS version 18 (SPSS
Inc., Chicago, IL, USA) was used to perform the statistical analyses. Statistical significance was
defined as a P-value <0.05.
Results
Baseline characteristics
The baseline patient characteristics are presented in Table 1. Sixty-three patients with ER-posi-
tive, HER2-negative tumors were included in the analyses. The median age of these patients
was 52 years (range: 28–75 years). Eleven patients had node-positive disease, and 3 had micro-
metastases. No patient in the study population had a stage higher than IIB.
Thirty-four (54%), 17 (27%), and 12 patients (19%) had a low, intermediate, and high RS,
respectively. Furthermore, 15 patients (24%) had tumors with higher RS (26), whereas 48
(76%) had tumors with lower RS (<26). The lower RS group tended to have tumors with
higher PR expression and lower Ki67 expression, compared with the higher RS group.
Comparisons cell death rates according to categorized RS
The mean CDR differed significantly according to categorized RS, with 17.3±10.8 in the low
RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in the high RS group
(P = 0.024, One-way ANOVA test; Fig 1A). The mean CDR was significantly higher in the
high RS group compared with the low RS group (P = 0.012, the Student’s t-test). However, a
significant difference of CDR between the low and intermediate RS groups or the intermediate
and high RS groups was not observed.
Moreover, when we compared the mean CDR according to dichotomized RS, a significant
difference was observed, with 19.1±13.2 in the lower RS group vs. 27.9±12.5 in the higher RS
group (P = 0.025; Fig 1B).
Correlation between continuous RS and continuous CDR
Pearson’s R test was performed to explore the relationship between continuous RS and contin-
uous CDR. A significant positive correlation was observed between the two continuous param-
eters (Pearson’s R = 0.337; P = 0.007; Fig 2).
Logistic regression analysis
The area under the receiver operating characteristic curve for continuous CDR was 0.701
(95% CI, 0.533–0.869, P = 0.031) for distinguishing high RS from low or intermediate RS (Fig
3). Youden’s index was the highest for CDR of 28.1. As a result, we defined the CDR cutoff as
30 to identify tumors with chemosensitivity within this study. Multivariate analysis with
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biologic parameters revealed that RS, ER and PR expression remained independent variables
associated with chemosensitivity (Table 2). High RS demonstrated the odds ratio (OR = 26.33;
95% CI = 1.69–410.0) for predicting tumors with chemosensitivity on the multivariate
analysis.
Discussions
Using in vitro chemoresponse assay, we provided evidence that tumors with high or higher RS
have superior chemo-responsiveness compared with tumors with low or lower RS. A linear
correlation between continuous RS and continuous CDR was also observed. Finally, we
showed that high RS was associated with chemosensitivity to doxorubicin independent of
other biologic parameters in ER-positive/HER2 negative tumors.
Our findings are in the line with previous studies that tumors with high RS have a higher
rate of pCR in neoadjuvant setting. In the study by Gianni et al, they showed that RS was posi-
tively associated with the likelihood of pCR [10]. Another study by Yardley et al. also sup-
ported this finding that achievement of pCR was only observed in tumors with high RS (0 of
36 with low or intermediate RS vs. 19 of 72 with high RS) [11]. Although these studies also
included ER-negative tumors, they provided evidence that tumors with high RS had a higher
probability of pCR compared with tumors with low or intermediate RS in neoadjuvant setting.
Conversely, the recent study including ER-positive/HER2-negative tumors alone showed that
Table 1. Baseline characteristics.
Variables Lower RS (N = 48) Higher RS (N = 15) P-value
Age (median, range) 49 (28–75) 56 (38–62) 0.344
Tumor size (median, range) 1.8 (0.9–4.0) 2.2 (0.9–3.5) 0.210
T stage 0.073
T1 30 (62) 5 (33)
T2 18 (38) 10 (67)
N stage 0.244
0 35 (73) 14 (93)
Micrometastasis 2 (4) 1 (7)
N1 11 (23) 0 (0)
Stage 0.232
I 23 (48) 4 (27)
II 25 (52) 11 (73)
Grade 0.142
I or II 40 (85) 10 (67)
III 7 (15) 5 (33)
Estrogen receptor a 1.000
High 39 (81) 12 (80)
Low 9 (19) 3 (20)
Progesterone receptor a 0.002
High 33 (69) 3 (20)
Low 15 (31) 12 (80)
Ki67 <0.001
20 7 (15) 10 (67)
<20 41 (85) 5 (33)
a High, Allred score 5–8; Low, Allred score 0–4
https://doi.org/10.1371/journal.pone.0187679.t001
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clinical response rate or tumor size reduction rate did not correlate with continuous or catego-
rized RS [15]. Notably, there is no case with pCR in the study. The rarity of pCR might be asso-
ciated with a discrepancy among those studies.
Also, there is another study which delivers NAC in ER-positive/HER2-negative patients
with higher RS (26) using core biopsy samples [16]. In these, the rate of pCR in both breast
and axilla was 14.3% (2 of 14). Despite of small number of patients, it supports that tumors
with higher RS have chance of pCR even though they are luminal/HER2-negative tumors.
Fig 1. Distributions and means of cell death rate (CDR) according to categorized recurrence score (RS). (A) The mean CDRs differed
significantly among the three groups (P = 0.024, One-way ANOVA test). The mean CDR was significantly higher in the high RS group compared
with the low RS group (P = 0.012, the Student’s t-test). However, a significant difference of CDR between the low and intermediate RS groups or the
intermediate and high RS groups was not observed. (B) The mean CDR was significantly higher in the higher RS group compared with the lower RS
group (P = 0.025, the Student’s t-test).
https://doi.org/10.1371/journal.pone.0187679.g001
Fig 2. Cubic spline curve of the cell death rate to doxorubicin as a function of recurrence score. A
significant positive correlation was observed between the two continuous parameters (Pearson’s R = 0.337;
P = 0.007).
https://doi.org/10.1371/journal.pone.0187679.g002
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A less sensitivity to chemotherapy in low RS tumors observed in our in vitro data also sup-
ports that tumors with low RS would be marginally benefited by the addition of chemotherapy.
A recent report from the subgroup of the TAILORX trial also shows that endocrine alone is
Fig 3. The receiver operating characteristic (ROC) curve for cell death rate (CDR) in relation to high
RS. The ROC curve yielded an area under the curve of 0.701 (95% CI, 0.533–0.869, P = 0.031). Youden’s
index was the highest for CDR of 28.
https://doi.org/10.1371/journal.pone.0187679.g003
Table 2. Binary logistic regression analysis for factors associated with chemosensitivity (cell death
rate30%).
Variables P value Odds Ratio 95% CI
Recurrence score
Low Ref
Intermediate 0.057 4.42 0.96–20.44
High 0.020 26.33 1.69–410.0
Histologic grade
I or II Ref
III 0.361 2.11 0.43–10.48
Estrogen receptor a
Higher Ref
Lower 0.020 26.6 1.69–418.64
Progesterone receptor a
Higher vs. Lower Ref
Lower 0.037 16.15 1.18–221.94
Ki67
<20% Ref
20% 0.646 1.49 0.27–8.27
a Higher, Allred score 5–8; Lower, Allred score 0–4.
https://doi.org/10.1371/journal.pone.0187679.t002
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adequate treatment for those with tumors that had a low RS among patients with hormone
receptor–positive, HER2-negative, axillary node–negative breast cancer [17]. In the study, they
had very low rates of recurrence at 5 years with endocrine therapy alone.
A small number of patients is major limitation in our study. The absence of clinical out-
come in relation to ATP-CRA and the restriction of the clinical application of ATP-CRA
guided chemotherapy is another weakness of our study. Although this study was conducted
using a retrospective design and had several limitations, our study provide in vitro data sup-
porting that tumors with high RS have an increased responsiveness to chemotherapy.
In conclusions, the chemosensitivity to doxorubicin measured by in vitro chemoresponse
assay was different according to the categorized RS. Our findings support that tumors with
higher RS has the higher chemosensitivity even though they are luminal/HER2-negative
tumors.
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